Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom

Autor: Dorothy Romanus, Shelby Corman, Francisco Javier Expósito González, Mohamad Mohty, Dasha Cherepanov, Wolfgang Knauf, Karthik Ramasamy, Haris G. Vikis, François Gavini, M. Janelle Cambron‐Mellott, Katharina Verleger, Youngmin Kwon
Přispěvatelé: Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Oxford University Hospitals NHS Trust, University of Oxford [Oxford]
Rok vydání: 2020
Předmět:
Male
Immunomodulatory drug
treatment outcomes
0302 clinical medicine
Maintenance therapy
Germany
Outcome Assessment
Health Care
Practice Patterns
Physicians'
Multiple myeloma
Aged
80 and over
Medical record
Disease Management
Hematology
General Medicine
Middle Aged
Prognosis
Combined Modality Therapy
3. Good health
Europe
multiple myeloma
retrospective studies
Treatment Outcome
medical records
Italy
030220 oncology & carcinogenesis
Cytogenetic Analysis
Retreatment
Cohort
Female
Original Article
France
medicine.drug
medicine.medical_specialty
Clinical Decision-Making
Newly diagnosed
03 medical and health sciences
Internal medicine
medicine
Humans
clinical practice patterns
Aged
business.industry
Retrospective cohort study
Original Articles
medicine.disease
United Kingdom
Proteasome inhibitor
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
030215 immunology
Zdroj: European Journal of Haematology
European Journal of Haematology, Wiley, 2020, 105 (3), pp.308-325. ⟨10.1111/ejh.13439⟩
ISSN: 1600-0609
0902-4441
Popis: International audience; ObjectivesThe treatment paradigm in newly diagnosed multiple myeloma (NDMM) is evolving toward individualized, risk-directed, and longer duration of therapy (DOT). The objective of this study was to describe treatment patterns and outcomes in non-transplant NDMM in four European countries.MethodsThis retrospective chart review included adults with NDMM diagnosed between January 1, 2012, and December 31, 2013 (early cohort), or April 1, 2016, and March 31, 2017 (recent cohort).ResultsAmong 836 patients, molecular testing was performed in 21% and 35% patients of early vs recent cohorts; proteasome inhibitor (PI)/alkylator combinations were the principal first-line (1 L) therapy (39% vs 43%). Use of immunomodulatory drug (IMID)/alkylator combinations declined from early to recent cohort (26% vs 13%) but IMID (7% vs 16%) use increased. Few patients (5%) received 1 L maintenance therapy. Two-thirds of patients were treated with a fixed duration intent, with a median 7-month 1 L DOT and progression-free survival (PFS) of 32.8 months in the early cohort. Both 1 L DOT and PFS were longer with oral compared to injectable regimens.ConclusionsAlthough frontline treatment patterns changed significantly, 1 L DOT is short. The uptake of molecular testing and 1 L maintenance is low. These results highlight areas of unmet need in NDMM.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje